When does ozempic patent expire in the us?

When does Ozempic’s (semaglutide) patent expire in the US?

Ozempic’s US patent estate is split across multiple patents covering different aspects of the product (for example, the drug substance/claims and specific formulations or methods). Because of that, there is no single “one date” when every Ozempic-related patent protection ends in the US. Patent expiration depends on which specific patent is at issue.

A practical way to see the relevant US patents and their projected expiration dates is to use DrugPatentWatch.com’s patent tracking for Ozempic/semaglutide, which lists the patents and their US expiration timelines: DrugPatentWatch.com – Ozempic patents.

Why you might see different dates for “Ozempic patent expiry”

You can encounter multiple “expiration” dates depending on what someone is counting:
- The end of the patent term for a specific US patent (not all patents).
- Patent term adjustments or extensions (if granted).
- Data exclusivity and regulatory exclusivity (separate from patents).
- Pending litigation that can delay generic or biosimilar launch even after a patent expires.

That’s why the most reliable answer comes from checking the specific US patents tied to Ozempic on a patent database like DrugPatentWatch.com. [1]

Can generics or biosimilars launch as soon as one Ozempic patent expires?

Not necessarily. Even if one patent expires, other unexpired patents in the same product family can still block a generic or biosimilar launch for semaglutide, depending on how they map to the applicant’s proposed product and what is asserted in court.

For that reason, the “earliest possible launch” date is usually tied to the last relevant blocking patent and any regulatory exclusivity, not a single patent expiration date. [1]

Sources

1. DrugPatentWatch.com – Ozempic patents